Akero Therapeutics, Inc. (AKRO) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à South San Francisco, CA, United States. Le PDG actuel est Andrew Cheng.
AKRO a date d'introduction en bourse 2019-06-20, 69 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $4.5B.
Akero Therapeutics, Inc. is a cardio-metabolic company focused on developing treatments for nonalcoholic steatohepatitis (NASH) and related metabolic disorders. The company's lead product candidate is efruxifermin (EFX), a fibroblast growth factor 21 analog designed to restore metabolic balance by protecting against cellular stress and regulating the metabolism of lipids, carbohydrates, and proteins throughout the body. Akero is advancing efruxifermin through clinical development, including the Phase 2a BALANCED study evaluating its efficacy in biopsy-confirmed NASH patients. Headquartered in South San Francisco, California, the company was founded in 2017 and rebranded from its former name, Pippin Pharmaceuticals, Inc., in May 2018.
